Borberg H, Gaczkowski A
Immun Infekt. 1984 Aug;12(4):193-200.
As compared to the widespread application of erythrocyte- and platelet transfusion, granulocyte substitution is still not without difficulties. In spite of the introduction of automated separation systems, the procurement of adequate numbers of granulocytes is not easy, mainly for numerical-technical reasons. Also, the need for an effective organizational background and a close functional connection of transfusion medicine and oncology are not appropriately observed. Whereas the results of studies investigating the prophylactic value of granulocyte transfusions remained negative, mainly due to an inadequate granulocyte dosage, the importance of earlier trials, demonstrating the therapeutic efficacy remains without objection, as subsequent studies also suffer from the transfusion of cells too low for clinical requirements. Granulocyte substitution is only one aspect of the biological defect compensation in the immunocompromised host. In spite of a reduced frequency of applications and the introduction of newer therapeutic developments, granulocyte transfusion, if sufficient cell numbers are applied, may well play a valuable role within the concept of biological defect compensation for the control of septicemia.
与红细胞和血小板输血的广泛应用相比，粒细胞替代仍然存在困难。尽管引入了自动化分离系统，但由于数值技术原因，获取足够数量的粒细胞并不容易。此外，对有效的组织背景以及输血医学与肿瘤学紧密功能联系的需求也未得到充分重视。尽管研究粒细胞输血预防价值的研究结果主要因粒细胞剂量不足而呈阴性，但早期试验证明其治疗效果的重要性并无争议，因为后续研究也存在输注细胞数量低于临床需求的问题。粒细胞替代只是免疫受损宿主生物缺陷补偿的一个方面。尽管应用频率降低且有了新的治疗进展，但如果应用足够数量的细胞，粒细胞输血在生物缺陷补偿概念中对控制败血症可能会发挥重要作用。
